THERAPY DOSSIER · th-021296d6efd3

Human neural stem cells secreting glial cell line-derived neurotrophic factor (GDNF)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22077363 ↗2011Reported benefit

Molecular mechanisms underlying effects of neural stem cells against traumatic axonal injury.

RatTBIFluid percussionSprague-DawleyMaleIntracerebral graft

Model: Parasagittal fluid percussion traumatic brain injury with traumatic axonal injury, plus in vitro rapid stretch injury

Human neural stem cell grafts reduced traumatic axonal injury by blocking abnormal amyloid precursor protein accumulation and counteracted the injury-induced rise in neuronal alpha-smooth muscle actin, with GDNF offsetting stretch-induced neurite shortening and actin aggregation through calcineurin…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.66. Machine-extracted fields require source verification.

Loading the evidence…